Sporos Bioventures

Tvardi Therapeutics, Inc. is a biotechnology company that specializes in developing innovative treatments for cancer, chronic inflammation, and fibrosis. The company's primary focus is on inhibitors of STAT3, a regulatory protein that plays a crucial role in various signaling pathways related to cancer cell survival and immune response. Tvardi's product pipeline includes TTI-101, an oral small-molecule inhibitor of STAT3, and its intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate that targets STAT3. Founded in 2017 and based in Houston, Texas, Tvardi Therapeutics aims to provide effective therapies for conditions such as breast and lung cancer, addressing significant medical needs in oncology and inflammatory diseases.

Tvardi Therapeutics, Inc. is a biotechnology company that specializes in developing innovative treatments for cancer, chronic inflammation, and fibrosis. The company's primary focus is on inhibitors of STAT3, a regulatory protein that plays a crucial role in various signaling pathways related to cancer cell survival and immune response. Tvardi's product pipeline includes TTI-101, an oral small-molecule inhibitor of STAT3, and its intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate that targets STAT3. Founded in 2017 and based in Houston, Texas, Tvardi Therapeutics aims to provide effective therapies for conditions such as breast and lung cancer, addressing significant medical needs in oncology and inflammatory diseases.

Stellanova Therapeutics is a private, development-stage biotechnology company in Houston Texas advancing therapies targeting the tumor microenvironment to treat cancers resistant to current therapies. The company’s platform centers on a drug pipeline targeting cancer-associated fibroblasts that spur tumors, an approach which has, to date, shown unprecedented anti-tumor activity in multiple resistant cancer models

Asylia Therapeutics is a biotechnology company established in 2019 in Houston, Texas, specializing in innovative immune-modulating therapies for autoimmune diseases, cancer, and infectious diseases. The company focuses on a drug pipeline that aims to modulate antigen presentation to the immune system, resulting in significant anti-tumor responses in various cancer models. Asylia's therapies are designed to assist healthcare providers in treating solid tumors, including breast and colon cancer, as well as hematologic malignancies such as multiple myeloma. By transforming scientific advancements into effective medicines, Asylia Therapeutics seeks to improve treatment outcomes for patients facing these challenging conditions.

Nirogy Therapeutics is a biotechnology company developing novel small molecules to target cellular transporters. The company is currently advancing a class of small molecules intended to disrupt metabolic and immune mechanisms operative in the tumor microenvironment. Follow-on platform programs are targeting additional disease pathways in oncology as well as autoimmune diseases.